Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Oct 6 · above the Ichimoku cloud · RSI 45 · MACD below its signal
None of the 29 investors followed here reported a position in SCPS in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a SCPS trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for SCPS.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 50.0 | -33.3 | 0.0 | 0.0 | 0.0 | 50.0 | -33.3 | 0.0 | 0.0 | 0.0 | 0.0% | ||
| 2025 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 33.3 | -25.0 | 0.0 | 100.0 | -33.3 | +33.3% |
| 2024 | -82.6 | -72.0 | -76.2 | 120.0 | -81.8 | -50.0 | 100.0 | 50.0 | 0.0 | 33.3 | -25.0 | 0.0 | −99.3% |
| 2023 | 33.3 | -42.1 | -19.3 | 6.8 | -23.0 | 8.0 | -7.4 | -20.0 | 14.2 | 0.0 | 13.8 | -17.2 | −55.8% |
| 2022 | -30.9 | -35.8 | -4.7 | -30.2 | -18.3 | 9.1 | -11.7 | -8.5 | -30.3 | 4.0 | -12.5 | -55.7 | −94.0% |
| 2021 | -30.9 | -9.6 | -8.8 | -13.3 | -3.4 | 0.8 | -34.9 | 18.1 | -24.4 | -18.6 | -26.6 | -34.1 | −89.0% |
| 2020 | — |
No analyst coverage for this instrument.
Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses. The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein. Scopus BioPharma Inc. has licensing agreements with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem. Scopus BioPharma Inc. was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is based in New York, New York.
No recent headlines.